Enter assignee name

% Expired Patents = 50.0

EPO Patents = 2

Forward Citations = 10

Loading Chart...

12 inventors (with patents filed for the assignee):

Yolande Misseri (4 out of 4 patents)

Benedikt Timmerman (4 out of 5 patents)

Daniel Ladant (3 out of 14 patents)

4. Claude Leclerc (3 out of 25 patents)

5. Xavier-Edmond-Edouard Preville (3 out of 3 patents)

6. Michael Esquerre (2 out of 2 patents)

7. Etienne Joly (2 out of 2 patents)

8. Anne Goubier (2 out of 2 patents)

9. Michael Esquerré (1 out of 1 patent)

10. Marie Momot (1 out of 1 patent)

11. Philippe Bridonneau (1 out of 1 patent)

12. Xavier Preville (1 out of 1 patent)

8 patents: Sort by Forward Citations

1. 9982024 - CyaA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses (2018-05-29),

2. 9902947 - CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses (2018-02-27),

3. 9827302 - HPV/CyaA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders (2017-11-28),

4. 9499809 - CyaA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses (2016-11-22),

5. 9486524 - Composition for eliciting a specific CTL response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells (2016-11-08),

6. 9387243 - Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof therapeutic uses thereof (2016-07-12),

7. 8637039 - Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof therapeutic uses thereof (2014-01-28),

8. 8628779 - Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof. therapeutic uses thereof (2014-01-14),

Genticel is a biotechnology company focused on developing immunotherapies to prevent and treat HPV-related diseases, such as cervical cancer. The company's lead product candidate, ProCervix, is a therapeutic vaccine designed to induce a specific immune response against HPV. Genticel is committed to improving women's health through innovative treatments and technologies.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

8 Patents

#3 in Labège

#2,020 in France

Labège, France

Genticel